PharmacoEconomics

Acknowledgement to Referees

Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

Diarmuid Coughlan, Oluwatomi Arisa, Katie Thomson, Ge Yu, Fiona Pearson, Ashleigh Kernohan, Sonia Garcia Gonzalez-Moral, Sheila Wallace, Stephen Rice

The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations

Daniel Hill-McManus

A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus

Marina Antoniou, Céu Mateus, Bruce Hollingsworth, Andrew Titman

Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis

Melissa Lannon, Taylor Duda, Alexander Mastrolonardo, Ellissa Huang, Amanda Martyniuk, Forough Farrokhyar, Feng Xie, Mohit Bhandari, Suneil K. Kalia, Sunjay Sharma

Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada

Aneeka Hafeez, Lauren E. Cipriano, Richard B. Kim, Gregory S. Zaric, Ute I. Schwarz, Sisira Sarma

Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis

Jedidiah I. Morton, Clara Marquina, Melanie Lloyd, Gerald F. Watts, Sophia Zoungas, Danny Liew, Zanfina Ademi

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer

Anthony J. Hatswell, Mohammad A. Chaudhary, Giles Monnickendam, Alejandro Moreno-Koehler, Katie Frampton, James W. Shaw, John R. Penrod, Rachael Lawrance

Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition

Daniel Tobias Michaeli, Thomas Michaeli